MDIC Announces Pathology ‘Collaborative Community’ With FDA Involvement
Executive Summary
This is MDIC’s third collaborative community, following groups for the US FDA’s Case for Quality and health technology.
You may also be interested in...
US FDA Touts Big Improvements In Product Review Process: Report
The US agency says it has either met or exceeded all its 2018-2020 strategic priorities, including simplifying core processes in its product review pathways.
FDA Debuts ‘Collaborative Communities’ With NESTcc, Optic Imaging Groups
The US agency is participating in collaborative communities centered around eye health and the development of real-world evidence, representing the first two of what the agency hopes will be at least 10 communities by the end of 2020.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.